IDEAYA and GSK entered into a broad strategic partnership in Synthetic Lethality. The partnership covers three IDEAYA Synthetic Lethality programs – MAT2A, Pol Theta and Werner Helicase. The companies have highly complementary Synthetic Lethality pipelines that target molecularly defined populations in several major solid tumors, including potentially lung, prostate, breast, colorectal, and ovarian cancer. The pipeline synergy creates strategic combination opportunities – for example, a potential to evaluate a clinical combination of IDEAYA’s MAT2A inhibitor, IDE397, and GSK’s Type I PRMT inhibitor, GSK3368715, in patients with MTAP-null tumors, which represent approximately 15% of all solid tumors.
Cancer Research UK / University of Manchester
IDEAYA has established a partnership with the Drug Discovery Unit at Cancer Research UK (CRUK) and the University of Manchester related to its Poly(ADP-ribose) glycohydrolase (PARG) program. Under this arrangement, IDEAYA has rights for development and commercialization of PARG inhibitors worldwide.
University of California San Diego
Building a sustainable pipeline of high value synthetic lethality based oncology programs is central to the IDEAYA mission. To compliment the internal efforts around target identification and validation we have an ongoing collaboration with Dr. Trey Ideker PhD Professor of Medicine and Bioengineering, UCSD. Dr. Ideker is a recognized leader in combining functional genomics and computational methods to understand gene-gene and pathway interactions at a “systems” level. Under a collaborative agreement, the Ideker Lab and IDEAYA are carrying out combinatorial CRISPR screens of key nodes of the DNA damage and repair pathway and human tumor suppressor genes, to identify next generation druggable synthetic lethality targets.
University of California San Francisco
IDEAYA is engaged in collaborative research with UCSF, which forms part of its strategic network for discovery and validation of biomarkers. Dr. Sourav Bandyopadhyay, PhD, is an Associate Professor in the Department of Bioengineering and Therapeutic Sciences of the Helen Diller Family Comprehensive Cancer Center at UCSF. Dr. Bandyopadhyay and IDEAYA are collaborating to identify and validate novel synthetic lethal relationships.
Novartis Institute for Biomedical Research (NIBR)
IDEAYA has an exclusive license with Novartis International Pharmaceutical Ltd. pursuant to which IDEAYA is developing and commercializing IDE196, a Phase 1 protein kinase C (PKC) inhibitor for the treatment of cancers having GNAQ and GNA11 mutations. IDE196 is a potent small molecule inhibitor of PKC demonstrating early clinical activity and tolerability in a Phase 1 clinical trial conducted by Novartis Institute for Biomedical Research. IDEAYA is conducting an ongoing Phase 1/2 clinical basket trial, and has exclusive rights for further clinical development of IDE196, together with unrestricted rights to commercialize worldwide.
IDEAYA has established a clinical trial collaboration and supply agreement with Pfizer Inc., pursuant to which Pfizer will supply IDEAYA with their MEK inhibitor, binimetinib, and with their cMET inhibitor, crizotinib. IDEAYA is evaluating IDE196 in combination with binimetinib, and in a separate arm of the clinical trial, in combination with crozotinib, in each case in GNAQ or GNA11 hotspot-mutated solid tumors, including metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer.